MTHFR and POTS

Could Methylation Influence Autonomic Function?

In clinical practice, patterns sometimes appear before research has explained them. One pattern Dr. Amy noticed is a high number of patients who have both common MTHFR gene polymorphisms and postural orthostatic tachycardia syndrome, better known as POTS.

There is not enough research to establish a direct relationship between MTHFR and POTS, but clinicaly it seems that there is a link. Common MTHFR variants are widespread, and POTS is a complex condition with several possible underlying mechanisms. However, MTHFR can influence folate metabolism, homocysteine, blood-vessel health, neurotransmitter pathways, and cellular stress responses, each of which may be relevant to how the autonomic nervous system regulates circulation.

What is POTS?

POTS is a form of "dysautonomia", meaning that the autonomic nervous system is not regulating involuntary functions normally. The autonomic nervous system helps control heart rate, blood pressure, blood vessel constriction, digestion, sweating, body temperature, and the distribution of blood throughout the body. When a healthy person stands, gravity pulls blood toward the legs and abdomen. The nervous system responds by tightening blood vessels and adjusting heart rate so that enough blood continues reaching the heart and brain.

In POTS, this doesn't happen properly. The heart speeds up dramatically to maintain circulation. In adults, POTS is generally diagnosed when heart rate increases by at least 30 beats per minute within 10 minutes of standing, without the sustained blood pressure drop that defines orthostatic hypotension. In adolescents, the usual threshold is a rise of at least 40 beats per minute. Symptoms must be persistent, and other causes of rapid heart beat, such as dehydration, anemia, infection, hyperthyroidism, medication effects, or significant blood loss, must be excluded.

Common symptoms of POTS include:

• Racing heart or pounding heartbeat when upright

• Dizziness or lightheadedness

• Feeling faint or occasionally fainting

• Brain fog

• Severe fatigue

• Exercise intolerance

• Shakiness or internal trembling

• Shortness of breath

• Headaches

• Nausea, bloating, or altered bowel function

• Temperature intolerance

• Purple or blotchy discoloration of the feet and legs

• Symptoms that improve when lying down

  
  

POTS is not simply anxiety, although the racing heart and adrenaline-like sensations can feel similar to a panic response. It can significantly affect school, work, exercise, relationships, and quality of life.

What Does MTHFR Do?

MTHFR stands for methylenetetrahydrofolate reductase. The gene provides instructions for an enzyme that helps convert folate into 5-methyltetrahydrofolate (5-MTHF). The body uses 5-MTHF to recycle homocysteine into methionine. Methionine can then be converted into S-adenosylmethionine, or SAMe, the major methyl donor used in hundreds of biochemical reactions.

The two common MTHFR variants are C677T and A1298C. These variants can reduce enzyme efficiency, but their effects differ greatly from person to person. Problems are more likely to emerge when a variant is combined with low folate or vitamin B12, poor riboflavin status, chronic illness, oxidative stress, restrictive eating, medication effects, or other genetic and environmental factors.

Theory 1: Linking MTHFR and POTS: Homocysteine and Blood-Vessel Regulation

One possible connection between MTHFR and POTS involves homocysteine.

When folate-dependent methylation is not working efficiently, homocysteine can rise. Elevated homocysteine has been associated with oxidative stress and endothelial dysfunction. The endothelium helps regulate whether blood vessels dilate or constrict. It does this partly through nitric oxide and other signaling molecules. Because standing requires rapid, precise regulation of blood-vessel tone, impaired endothelial signaling could theoretically make orthostatic compensation more difficult.

This remains a hypothesis. Mild elevations in homocysteine do not automatically cause vascular dysfunction, and elevated homocysteine has not been established as a typical cause of POTS. Nevertheless, measuring homocysteine if either MTHFR or POTS or both are present could help provide avenues of care.

Theory 2 Linking MTHFR and POTS: Methylation and Catecholamine Balance

Standing activates the sympathetic nervous system, which uses catecholamines such as epinephrine and norepinephrine as signals. Norepinephrine helps tighten blood vessels and maintain blood pressure when gravity pulls blood downward.The enzymes involved in producing and breaking down dopamine, norepinephrine, and epinephrine interact with methylation pathways. For example, catechol-O-methyltransferase, or COMT, uses SAMe to methylate catechol compounds.

If methyl-donor availability is altered, catecholamine processing changes. In a susceptible person, this might affect the intensity or duration of sympathetic signals. This could be relevant to hyperadrenergic POTS, a pattern characterized by pronounced sympathetic activation, palpitations, tremor, anxiety-like sensations, sweating, and sometimes increased blood pressure on standing.This pathway is complex. MTHFR could be one contributing factor, but high or low norepinephrine for other reasons, slow COMT activity, or hormonal dysregulation all contribute to hyperadrenergic POTS.

Theory 3 Linking MTHFR and POTS: Nutrient Deficiencies that Affect Nerves and Circulation

Folate, vitamin B12, vitamin B6, riboflavin, iron, and other nutrients support red-blood-cell production, nerve health, energy production, and methylation. Deficiencies may contribute to fatigue, neuropathy, weakness, palpitations, or poor exercise tolerance.

Iron deficiency is particularly important because it may worsen tachycardia and orthostatic symptoms even before severe anemia develops. Vitamin B12 deficiency can affect peripheral and autonomic nerves. Low food intake, digestive symptoms, restrictive diets, heavy menstrual bleeding, and malabsorption can all increase these risks.

MTHFR can contribute to functional nutritional deficiencies, but in this situation it is one piece of a much larger puzzle.

Theory 4 Linking MTHFR and POTS: Oxidative Stress, Inflammation, and Small-Fiber Nerves

Some people with POTS have small-fiber neuropathy, which can affect the tiny autonomic nerves responsible for tightening blood vessels in the legs. Others appear to have immune-mediated or post-infectious forms of the condition. Methylation helps support antioxidant defenses, cell repair, membrane production, and immune regulation. Impaired folate or B12 metabolism could therefore theoretically add to oxidative or neurologic stress.

Again, this does not establish MTHFR as a cause of neuropathic or autoimmune POTS, but it could be a contributor. Methylation and nutrient status may influence how well the nervous system recovers from illness or manages ongoing inflammation.

What Can You Do For POTS?

Treatment should begin with a proper diagnosis. Your doctor may use a standing test or a tilt-table test and order bloodwork to rule out anemia, thyroid disease, electrolyte disorders, nutrient deficiencies, infection, adrenal disorders, and other causes. First-line POTS care often includes increasing fluid intake and, when medically appropriate, sodium intake. This helps expand circulating blood volume. Some people benefit from electrolyte solutions rather than plain water alone. Extra salt is not appropriate for everyone, particularly people with kidney disease, heart disease, or certain forms of hypertension, so individualized guidance matters.

Compression garments that cover the abdomen and legs can reduce blood pooling. Small meals may be better tolerated than very large meals because digestion redirects blood toward the abdomen. Exercise can be extremely helpful, but beginning upright exercise too aggressively may cause a major setback. Many programs start with recumbent cycling, rowing, swimming, or floor-based strengthening. Training is advanced gradually as circulation and conditioning improve. Medications may also be appropriate. Depending on the individual pattern, clinicians may use treatments that increase blood volume, improve vascular constriction, reduce excessive heart rate, or calm sympathetic activation.

Supporting Methylation safely

For a patient with both POTS and an MTHFR polymorphism, useful testing may include:

• Homocysteine

• Complete blood count

• Ferritin and iron studies

• Vitamin B12 and methylmalonic acid

• Folate

• Vitamin B6 when indicated

• Thyroid testing

• Electrolytes and kidney function

  
  

Treatment should correct actual deficiencies rather than reacting to the gene result alone.

Folate-rich foods include leafy greens, lentils, beans, asparagus, avocado, and citrus. Vitamin B12 is found in animal foods and fortified products. Riboflavin is available from eggs, dairy products, meat, almonds, and mushrooms. Choline and betaine, found in foods such as eggs, beets, spinach, seafood, and quinoa, provide additional support for methylation.

Some people tolerate methylfolate well. Others feel overstimulated by high doses, particularly when they already experience tachycardia, insomnia, or adrenaline-like symptoms. Starting low, changing one variable at a time, and working with a knowledgeable practitioner is more useful than taking a large “methylation stack.”

Avoiding folic acid is also crucial to support methylation. Folic acid is metabolized slowly, and research shows that unmetabolized folic acid leads to a "pseudo MTHFR deficiency" even in people without MTHFR gene variants, and it exacerbates problems caused by the MTHFR gene.

The overlap between MTHFR polymorphisms and POTS is an interesting clinical observation, but it has not yet been proven by direct research.Many plausible connections exist, and these ideas can guide thoughtful testing, but more research is needed to truly understand this phenomenon.

POTS is real, physical, and often treatable. The most useful approach is to identify the individual pattern. Hypovolemic, neuropathic, hyperadrenergic, autoimmune, post-infectious, deconditioned, or mixed are all possible POTS types. Conventional contributors and correctable metabolic stressors must all be addressed, and MTHFR is one piece of that puzzle.

References

Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome: current experience and concepts. Nature Reviews Neurology. 2021;17(10):601–613. doi:10.1038/s41582-021-00522-2.

Sheldon RS, Grubb BP II, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41–e63. doi:10.1016/j.hrthm.2015.03.029.

Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome and related disorders of chronic orthostatic intolerance. Canadian Journal of Cardiology. 2020;36(3):357–372. doi:10.1016/j.cjca.2019.12.024.

Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome—diagnosis, physiology, and prognosis. Autonomic Neuroscience. 2018;215:3–11. doi:10.1016/j.autneu.2018.02.005.

Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Current Neurology and Neuroscience Reports. 2015;15(9):60. doi:10.1007/s11910-015-0583-8.

Blitshteyn S, Fedorowski A. Autoimmunity in syndromes of orthostatic intolerance: an updated review. Autoimmunity Reviews. 2024;23(5):103526. doi:10.1016/j.autrev.2024.103526.

Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Autonomic Neuroscience. 2018;215:20–27. doi:10.1016/j.autneu.2018.07.001.

George SA, Bivens TB, Howden EJ, et al. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm. 2016;13(4):943–950. doi:10.1016/j.hrthm.2015.12.012.

Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics. 1995;10(1):111–113. doi:10.1038/ng0595-111.

Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metabolism. 2017;25(1):27–42. doi:10.1016/j.cmet.2016.08.009.

Lai WKC, Kan MY. Homocysteine-induced endothelial dysfunction. Annals of Nutrition and Metabolism. 2015;67(1):1–12. doi:10.1159/000437098.

Pushpakumar S, Kundu S, Sen U. Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Current Medicinal Chemistry. 2014;21(32):3662–3672. doi:10.2174/0929867321666140706142335.